Factor Xa inhibitors:: S1 binding interactions of a series of N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}sulfonamides

被引:46
作者
Chan, Chuen
Borthwick, Alan D.
Brown, David
Burns-Kurtis, Cynthia L.
Campbell, Matthew
Chaudry, Laiq
Chung, Chun-wa
Convery, Maire A.
Hamblin, J. Nicole
Johnstone, Lisa
Kelly, Henry A.
Kleanthous, Savvas
Patikis, Angela
Patel, Champa
Pateman, Anthony J.
Senger, Stefan
Shah, Gita P.
Toomey, John R.
Watson, Nigel S.
Weston, Helen E.
Whitworth, Caroline
Young, Robert J.
Zhou, Ping
机构
[1] GlaxoSmithKline Res & Dev Ltd, Med Res Ctr, CVU UK Med Chem Dept, Stevenage SG1 2NY, Herts, England
[2] GlaxoSmithKline Res & Dev Ltd, Med Res Ctr, Screening & Cpd Profiling UK, Stevenage SG1 2NY, Herts, England
[3] GlaxoSmithKline Res & Dev Ltd, Med Res Ctr, Assay Dev UK, Stevenage SG1 2NY, Herts, England
[4] GlaxoSmithKline Res & Dev Ltd, Med Res Ctr, Computat & Struct Chem, Stevenage SG1 2NY, Herts, England
[5] GlaxoSmithKline Res & Dev Ltd, Med Res Ctr, CVU UK DMPK Dept, Stevenage SG1 2NY, Herts, England
[6] GlaxoSmithKline, Vasc Inflammatory Dis, King Of Prussia, PA 19406 USA
关键词
D O I
10.1021/jm060870c
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Factor Xa inhibitory activities for a series of N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}sulfonamides with different P1 groups are described. These data provide insight into binding interactions within the S1 primary specificity pocket; rationales are presented for the derived SAR on the basis of electronic interactions through crystal structures of fXa-ligand complexes and molecular modeling studies. A good correlation between in vitro anticoagulant activities with lipophilicity and the extent of human serum albumin binding is observed within this series of potent fXa inhibitors. Pharmacokinetic profiles in rat and dog, together with selectivity over other trypsin-like serine proteases, identified 1f as a candidate for further evaluation.
引用
收藏
页码:1546 / 1557
页数:12
相关论文
共 78 条
[1]   Inhibition of Factor Xa: A potential target for the development of new anticoagulants [J].
Alexander J.H. ;
Singh K.P. .
American Journal of Cardiovascular Drugs, 2005, 5 (5) :279-290
[2]   6-METHYL-2-NAPHTHALENESULFONATE (MENASYLATE) - NEW AND USEFUL LEAVING GROUP FOR TRIFLUOROACETOLYSIS [J].
ANDO, T ;
SAITO, Y ;
YAMAWAKI, J ;
MORISAKI, H ;
SAWADA, M ;
YUKAWA, Y .
JOURNAL OF ORGANIC CHEMISTRY, 1974, 39 (16) :2465-2466
[3]  
[Anonymous], JOINT CCP4 ESF EAMCB
[4]   THE CCP4 SUITE - PROGRAMS FOR PROTEIN CRYSTALLOGRAPHY [J].
BAILEY, S .
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 1994, 50 :760-763
[5]  
BAUDIN JB, 1993, B SOC CHIM FR, V130, P856
[6]   Fondaparinux: an update on new study results [J].
Bauersachs, RM .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2005, 35 :27-32
[7]  
Boos C J, 2005, Eur J Intern Med, V16, P267, DOI 10.1016/j.ejim.2005.02.005
[8]   Characterization of persistent intramolecular C-H•••X(N,O) bonds in solid state and solution [J].
Cappelli, A ;
Giorgi, G ;
Anzini, M ;
Vomero, S ;
Ristori, S ;
Rossi, C ;
Donati, A .
CHEMISTRY-A EUROPEAN JOURNAL, 2004, 10 (13) :3177-3183
[9]  
CHAN C, 2002, Patent No. 2002100830
[10]   Discovery of an orally efficacious inhibitor of coagulation factor Xa which incorporates a neutral P1 ligand [J].
Choi-Sledeski, YM ;
Kearney, R ;
Poli, G ;
Pauls, H ;
Gardner, C ;
Gong, Y ;
Becker, M ;
Davis, R ;
Spada, A ;
Liang, G ;
Chu, V ;
Brown, K ;
Collussi, D ;
Leadley, R ;
Rebello, S ;
Moxey, P ;
Morgan, S ;
Bentley, R ;
Kasiewski, C ;
Maignan, S ;
Guilloteau, JP ;
Mikol, V .
JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (05) :681-684